Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation
Matthew P. Cheng(McGill University Health Centre), Francisco M. Marty(Brigham and Women's Hospital), Amanda E. Kusztos(MACOM (United States)), Vincent T. Ho(Dana-Farber Cancer Institute), Candace Hsieh(Dana-Farber Cancer Institute), Meghan A. Baker(Brigham and Women's Hospital), Sarah P. Hammond(Dana-Farber Cancer Institute), Brett Glotzbecker(Dana-Farber Cancer Institute), Tyler D. Bold(University of Minnesota Medical Center), Lindsey R. Baden(Brigham and Women's Hospital)
Cited by 37
Related Papers
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
|New England Journal of Medicine|2020|1.4k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k